Selexys Pharmaceuticals Initiates Enrollment in Phase I Clinical Study of SelG1

This study will evaluate the safety and pharmacology of SelG1 prior to advancement into a Phase II trial in patients with sickle cell disease.

Selexys Pharmaceuticals, a privately held biopharmaceutical company, announced yesterday that it has initiated enrollment in a Phase I clinical study of its lead compound, SelG1, a humanized anti-P-selectin antibody.  

The placebo-controlled, double-blind, first-in-human, ascending single dose and multiple dose study of SelG1 will enroll approximately 30 healthy subjects. This study will evaluate the safety and pharmacology of SelG1 prior to advancement into a Phase II trial in patients with sickle cell disease.

"This Phase I study represents the first step in understanding the potential of SelG1 to address the unmet medical need in sickle cell disease and we are excited to initiate the clinical development of this novel compound,"